FDA guidance released on June 12 broadens a safe harbor that allows medical product manufacturers to communicate with payers, PBMs, formulary committees and similar entities. A primary goal is to make it easier to base payments on outcomes not mentioned on product labels, but there could be broader effects in the loosened restrictions oncommunications between medical product developers and payers.
read full article ›